Chart review for CML patients previously treated with certain pills
Part of Blood & lymphatic, Cancer clinical trials.
This study reviews existing medical records of people with chronic myelogenous leukemia (CML) who were treated with specific FDA-approved targeted tablets (tyrosine kinase inhibitors) at MD Anderson but not on an MD Anderson clinical trial. It may help the hospital understand how these medicines are used in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have been diagnosed with CML (chronic, accelerated, or blast phase)
- Received at least one FDA-approved CML pill that targets the disease (a tyrosine kinase inhibitor such as imatinib, dasatinib, or nilotinib)
- Were treated outside of an MD Anderson clinical trial
- Had at least one clinic visit at MD Anderson (MDACC)
- No other exclusion requirements are listed for this chart review
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new daily pill called TGRX-678 for people with chronic-phase CML who have not responded well to or cannot tolerate other CML treatments. It aims to see if the drug is safe and if it can help control the leukemia.
This trial tests a new combination treatment for people with chronic myeloid leukemia (CML) whose disease is resistant to or intolerant of current standard drugs. The goal is to see if the study drug works better when combined with another drug, and to check its safety.
This study tests an experimental pill (TQB3911) for people with chronic myeloid leukemia (CML) who have not responded well to or could not tolerate standard treatments. The goal is to find out if the drug is safe and what side effects it may cause.
This study tests a new oral medication for people with chronic myeloid leukemia (CML) who have already tried at least three other treatments without success or with side effects. The goal is to see if this new drug can help control the leukemia.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
Hear when a new Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.